^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:Ameile (aumolertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

    Excerpt:
    ...- Lung adenocarcinoma patient with EGFR sensitive mutation as confirmed by needle biopsy;...
    Trial ID:
    LungMate-007
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer

    Excerpt:
    ...Patients with primary non-small cell lung cancer with 2 common EGFR mutations（EGFR 19 Del or 21 L858R）; 6. ...
    Trial ID:
    ChiCTR2200062887
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ELCC 2023
    Title:

    98P - Adjuvant aumolertinib in resected EGFR-Mutated Non-Small-Cell Lung Cancer: a multiple-center real-world experience

    Published date:
    03/23/2023
    Excerpt:
    A total of 215 patients who underwent radical lung cancer surgery with EGFR-sensitizing mutations from four different medical centers were enrolled and received aumolertinib...2-year DFS was 99%.... Our study further demonstrates the pronounced efficacy of aumolertinib in the postoperative adjuvant treatment of NSCLC with an excellent safety profile.